478 results on '"Gross GJ"'
Search Results
2. Role of 1Opiate Receptors in Regulation of Contractility in Isolated Rat Heart during Normal Oxygenation and Ischemia/Reperfusion
- Author
-
T. V. Lasukova, Leonid N. Maslov, Iu B Lishmanov, and Gross Gj
- Subjects
Agonist ,Inotrope ,medicine.medical_specialty ,Enkephalin ,medicine.drug_class ,Stimulation ,Biology ,General Biochemistry, Genetics and Molecular Biology ,Contractility ,Endocrinology ,Opioid ,Internal medicine ,medicine ,General Agricultural and Biological Sciences ,Receptor ,Perfusion ,medicine.drug - Abstract
The experiments on isolated rat heart demonstrated significant decrease in reperfusion-induced damage of cardiomyocytes by addition of selective delta 1 receptor agonist DPDPE (0.1 mg/l) to the perfusion solution. On the contrary, no cardioprotective effect was observed for 0.5 mg/l concentration of the peptide or after its intravenous injection. Stimulation of the cardiac delta 1 opioid receptors by intravenous injection of 0.5 mg/kg DPDPE or its addition to the perfusion solution decreased myocardial contractility both in conditions of normal oxygenation and during reperfusion. Thus, the cardioprotective and negative inotropic effect of DPDPE is mediated by activation of the cardiac delta 1 opioid receptors.
- Published
- 2004
3. Role of Opiate Receptors and ATP-Dependent Potassium Channels of Mitochondria in the Formation of Myocardial Adaptive Resistance to the Arrhythmogenic Effect of Ischemia and Reperfusion
- Author
-
D. S. Ugdyzhekova, J. B. Stefano, Yu. B. Lishmanov, Leonid N. Maslov, Bogomaz Sa, N. V. Naryzhnaya, Gross Gj, and A. B. Krylatov
- Subjects
Agonist ,medicine.drug_class ,Antagonist ,Ischemia ,Stimulation ,Biology ,Mitochondrion ,Pharmacology ,medicine.disease ,General Biochemistry, Genetics and Molecular Biology ,Potassium channel ,Glibenclamide ,Coronary occlusion ,medicine ,General Agricultural and Biological Sciences ,medicine.drug - Abstract
Preliminary stimulation of opiate receptors (ORs) by intravenous administration of μ agonist DALDA (0.5 mg/kg), δ1 agonist DPDPE (0.5 mg/kg), and κ agonist (-)-U-50.488 (1 mg/kg) increases rat myocardial resistance to arrhythmogenic effect of coronary occlusion (10 min) and reperfusion (10 min). Activation of δ2 ORs (DSLET, 0.5 mg/kg) has no effect on the incidence rate of ischemic and reperfusion arrhythmias. Preliminary administration of glibenclamide (0.3 mg/kg), an inhibitor of KATP channels, blocks the antiarrhythmic effect of DALDA and DPDPE. Repeated short-term exposures of rats to immobilization within two weeks increases the heart tolerance to the arrhythmogenic effect of coronary occlusion and reperfusion. This effect disappears after administration of CTAP (0.5 mg/kg), a μ antagonist, or injection of 5-hydroxydecanoate (5 mg/kg), an inhibitor of mitochondrial KATP channels. The selective antagonists of δ and κ ORs have no effect on cardiac adaptation-induced resistance to the arrhythmogenic effect of ischemia and reperfusion. We believe that stimulation of μ, δ, and κ ORs increases myocardial tolerance to the arrhythmogenic effect of ischemia and reperfusion through activation of KATP channels. The antiarrhythmic effect of the adaptation is mediated by stimulation of μ ORs and mitochondrial KATP channels.
- Published
- 2003
4. [Untitled]
- Author
-
Leonid N. Maslov, N. V. Naryzhnaya, Yu. B. Lishmanov, and Gross Gj
- Subjects
endocrine system ,medicine.medical_specialty ,Myocardial reperfusion ,business.industry ,Receptor specificity ,General Medicine ,Coronary reperfusion ,Pharmacology ,General Biochemistry, Genetics and Molecular Biology ,Blockade ,chemistry.chemical_compound ,Endocrinology ,nervous system ,chemistry ,Internal medicine ,polycyclic compounds ,Medicine ,DADLE ,Antiarrhythmic effect ,business ,Opioid peptide ,Receptor - Abstract
Nonselective agonists of mu- and delta-opioid receptors dalargin (D-Ala2,Leu5,Arg6-enkephalin) and DADLE (D-Ala2,D-Leu5-enkephalin) administered immediately before coronary reperfusion in a dose of 0.1 mg/kg prevented the development of ventricular arrhythmias. Blockade of mu-opioid receptors abolished the antiarrhythmic effect of these peptides. Hence, antiarrhythmic activity of dalargin and DADLE is primarily associated with activation of mu-opioid receptors.
- Published
- 2002
5. Farmaci antianginosi
- Author
-
Gross GJ, ROSSI, Francesco, Gross, Gj, and Rossi, Francesco
- Published
- 1992
6. Predictors of Torsades de Pointes in rabbit ventricles perfused with sedating and nonsedating histamine H-1-receptor antagonists
- Author
-
Gilbert, JD, Cahill, SA, McCartney, DG, Lukas, A, Gross, GJ, and University of Manitoba
- Subjects
QT interval ,TERFENADINE ,ARRHYTHMIAS ,PHARMACOKINETICS ,CHANNELS ,ventricular arrhythmias ,Langendorff preparation ,ASTEMIZOLE OVERDOSE ,MECHANISMS ,rabbit ventricle ,DE-POINTES ,CETIRIZINE ,H-1-receptor antagonists ,HEART ,cardiovascular diseases ,ANTIHISTAMINES - Abstract
Several nonsedating histamine H-1-receptor antagonists are associated with torsades de pointes ventricular tachycardia. The objectives of this study were to: (i) compare electrocardiographic, monophasic action potential, and arrhythmogenic effects of sedating and nonsedating H-1-receptor antagonists, and (ii) identify correlates of drug-induced torsades de pointes in an isolated ventricle model. Isolated, electrically paced (1-3 Hz) rabbit ventricles were Langendorff-perfused with either drug-free Tyrode's solution or one of the following: (i) the sedating H-1-receptor antagonist hydroxyzine (0.1-30 mu M), (ii) cetirizine, a nonsedating metabolite of hydroxyzine (1-300 mu M), and (iii) the nonsedating, putatively arrhythmogenic H-1-receptor antagonist astemizole (0.1-30 mu M). Volume conducted electrocardiographic signals and monophasic action potentials from the periapical left ventricular endocardium and epicardium were recorded. There were no apparent changes in control (n = 15) or hydroxyzine-perfused (n = 7) hearts. Cetirizine (n = 13) produced a mild biphasic electrocardiographic QT interval prolongation and was associated with early afterdepolarizations, but not with torsades de pointes. Astemizole (n = 11) lengthened QT intervals, and at high concentration (30 mu M) induced torsades de pointes in 10 of 11 hearts (P < 0.001 vs. all other groups). These findings are consistent with previously reported repolarizing current inhibition by cetirizine, but may additionally indicate "compensatory" inhibition of inward currents at higher concentrations. By contrast, astemizole-induced changes are consistent with unopposed repolarizing current inhibition.
- Published
- 2000
7. POTASSIUM CHANNEL OPENERS, PINACIDIL AND EMD 52692, REVERSE ATRIOVENTRICULAR-BLOCK CAUSED BY BUPIVACAINE IN THE ISOLATED GUINEA-PIG HEART
- Author
-
BOSNJAK, ZJ BOBAN, M STOWE, DF GROSS, GJ PIEPER, GM KAMPINE, JP
- Subjects
PINACIDIL, EMD 52692, BUPIVACAINE - Abstract
POTASSIUM CHANNEL OPENERS, PINACIDIL AND EMD 52692, REVERSE ATRIOVENTRICULAR-BLOCK CAUSED BY BUPIVACAINE IN THE ISOLATED GUINEA-PIG HEART
- Published
- 1992
8. REPERFUSION PROTECTION BY INHIBITION OF Na+ H+ EXCHANGE BEFORE GRADED ISCHEMIA IN ISOLATED GUINEA PIG HEARTS
- Author
-
Varadarajan, SG, primary, Heisner, JS, additional, Parsons, T, additional, An, JZ, additional, Smart, SC, additional, Weber, CC, additional, Novalija, E, additional, Gross, GJ, additional, and Stowe, DF, additional
- Published
- 1999
- Full Text
- View/download PDF
9. Isoflurane postconditioning protects against reperfusion injury by preventing mitochondrial permeability transition by an endothelial nitric oxide synthase-dependent mechanism.
- Author
-
Ge ZD, Pravdic D, Bienengraeber M, Pratt PF Jr, Auchampach JA, Gross GJ, Kersten JR, Warltier DC, Ge, Zhi-Dong, Pravdic, Danijel, Bienengraeber, Martin, Pratt, Phillip F Jr, Auchampach, John A, Gross, Garrett J, Kersten, Judy R, and Warltier, David C
- Published
- 2010
- Full Text
- View/download PDF
10. Vitamin D insufficiency and musculoskeletal symptoms in breast cancer survivors on aromatase inhibitor therapy.
- Author
-
Waltman NL, Ott CD, Twiss JJ, Gross GJ, and Lindsey AM
- Published
- 2009
- Full Text
- View/download PDF
11. Bone mineral density and bone turnover in postmenopausal women treated for breast cancer.
- Author
-
Waltman NL, Ott CD, Twiss JJ, Gross GJ, Lindsey AM, and Moore TE
- Published
- 2008
- Full Text
- View/download PDF
12. Diabetes abolishes morphine-induced cardioprotection via multiple pathways upstream of glycogen synthase kinase-3beta.
- Author
-
Gross ER, Hsu AK, Gross GJ, Gross, Eric R, Hsu, Anna K, and Gross, Garrett J
- Abstract
The cardioprotective effect of opioids or glycogen synthase kinase (GSK) inhibitors given at reperfusion has not been investigated in diabetes models. Therefore, nondiabetic (NDBR) or streptozotocin-induced diabetic (DBR) rat hearts were subjected to 30 min of ischemia and 2 h of reperfusion. Groups of NDBR or DBR were administered either vehicle, morphine (0.3 mg/kg), or the GSK inhibitor SB216763 (0.6 mg/kg) 5 min before reperfusion. SB216763 (but not morphine) reduced infarct size in DBRs (44 +/- 1* and 55 +/- 2%, respectively), while both agents reduced infarct size in NDBRs versus untreated NDBRs or DBRs (44 +/- 3*, 42 +/- 3*, 60 +/- 2, and 56 +/- 2%, respectively, *P < 0.001). Morphine-induced phospho- (P-)GSK3beta was reduced 5 min after reperfusion in DBRs compared with NDBRs (0.83 +/- 0.29 and 1.94 +/- 0.12 [P < 0.05] pg/microg tissue, respectively). The GSK3beta mediators, P-Akt, P-extracellular signal-related kinase (ERK)1, and P-signal transducer and activator of transcription (STAT)3, were also significantly reduced in untreated DBR compared with NDBR rats. Morphine-induced elevations of P-Akt, P-ERK1, P-p70s6, P-janus-activated kinase-2, and P-STAT3 in NDBRs were also blunted in DBRs. H9C2 cells raised in 25 mmol/l compared with 5.56 mmol/l glucose media also demonstrated reduced morphine-induced P-GSK3beta, P-Akt, P-STAT3, and P-ERK1 after 15 min. Hence, acute GSK inhibition may provide a novel therapeutic strategy for diabetic patients during an acute myocardial infarction, whereas morphine is less effective due to signaling events that adversely affect GSK3beta. [ABSTRACT FROM AUTHOR]
- Published
- 2007
- Full Text
- View/download PDF
13. Health behaviors in breast cancer survivors experiencing bone loss.
- Author
-
Twiss JJ, Gross GJ, Waltman NL, Ott CD, and Lindsey AM
- Subjects
- *
LIFESTYLES , *HEALTH , *BREAST cancer , *BONES , *CALCIUM - Published
- 2006
- Full Text
- View/download PDF
14. Challenges of recruitment of breast cancer survivors to a randomized clinical trial for osteoporosis prevention.
- Author
-
Ott CD, Twiss JJ, Waltman NL, Gross GJ, and Lindsey AM
- Published
- 2006
- Full Text
- View/download PDF
15. Postmenopausal breast cancer survivors at risk of osteoporosis: physical activity, vigor, and vitality.
- Author
-
Gross GJ, Ott CD, Lindsey AM, Twiss JJ, and Waltman N
- Abstract
PURPOSE/OBJECTIVES: To test a multicomponent intervention to prevent and treat osteoporosis in breast cancer survivors. DESIGN: Descriptive, correlational. SETTING: Midwestern urban and rural sites. SAMPLE: 27 postmenopausal breast cancer survivors between the ages of 42-65 who had completed treatment, except for tamoxifen, and were not candidates for hormone replacement therapy. METHODS: Bone mineral density (BMD) of the hip, spine, and forearm was measured using dual-energy x-ray absorptiometry. Physical activity was recorded using the Seven-Day Physical Activity Recall-Adapted, which classifies activities as light, moderate, hard, or very hard. Vigor was measured with the eight-item subscale of the Profile of Mood State based on the previous week. Vitality was measured using the four-question subscale of the Medical Outcomes Study 36-Item Short Form Health Survey. MAIN RESEARCH VARIABLES: Physical activity, vigor, vitality, and BMD. FINDINGS: More than half reported no very hard physical activity, and 37% reported no hard activity. The association of vigor with total metabolic equivalents for combined moderate, hard, and very hard activities was significant (r = 0.536, p = 0.007), as were the hours spent in the combined moderate to very hard activities. No relationship was found between vigor, vitality, or any level of activity and BMD. CONCLUSIONS: Survivors reported high levels of perceived vigor and vitality but spent more time engaged in light versus hard or very hard activities. Positive correlations between higher levels of vitality and vigor with metabolic equivalents support the idea that activity promotes perceptions of energy and positive feelings. IMPLICATIONS FOR NURSING: Breast cancer survivors are at risk for osteoporosis. Nurses should be aware of increased risk, recommend screening for bone health, and encourage physical activity. [ABSTRACT FROM AUTHOR]
- Published
- 2002
- Full Text
- View/download PDF
16. Bone mineral density in postmenopausal breast cancer survivors.
- Author
-
Twiss JJ, Waltman N, Ott CD, Gross GJ, Lindsey AM, and Moore TE
- Abstract
PurposeThe overall purpose of this longitudinal 18-month study was to test the feasibility and effectiveness of a multicomponent intervention for prevention and treatment of osteoporosis. The purpose of this article is to describe the baseline bone mineral density (BMD) findings for 30 postmenopausal women and to compare these BMD findings to time since menopause, body mass index, and tamoxifen use.Data SourcesBaseline data of BMD findings for 30 postmenopausal women, who have had a variety of treatments including surgery, adjuvant chemotherapy and or tamoxifen, and are enrolled in the 18-month longitudinal study. A demographic questionnaire and a three day dietary record were used to collect baseline data.ConclusionsEighty percent of the women with breast cancer history had abnormal BMDs at baseline (t-scores below -1.00 SD). Thinner women showed a greater risk for accelerated trabecular bone loss at the spine and hip.Implications for PracticeThese findings suggest the need for early BMD assessments and for aggressive health promotion intervention strategies that include a multifaceted protocol of drug therapy for bone remodeling, 1500 mg of daily calcium, 400 IU vitamin D and a strength weight training program that is implemented immediately following chemotherapy treatment and menopause in this high risk population of women. [ABSTRACT FROM AUTHOR]
- Published
- 2001
- Full Text
- View/download PDF
17. Sildenafil and endothelial dysfunction in humans.
- Author
-
Gross GJ
- Published
- 2005
18. Analysis of coronary vascular beta receptors in situ
- Author
-
Gross, GJ, primary and Feigl, EO, additional
- Published
- 1975
- Full Text
- View/download PDF
19. Sinus bradycardia after intravenous pulse methylprednisolone.
- Author
-
Akikusa JD, Feldman BM, Gross GJ, Silverman ED, and Schneider R
- Published
- 2007
- Full Text
- View/download PDF
20. Increased Prevalence of the Electrocardiographic Early Repolarization Pattern in Young Patients With Vagally Mediated Syncope: A Case-Control Study.
- Author
-
Singla M, Tyrrell PN, Khural M, and Gross GJ
- Abstract
Background: Electrocardiographic early repolarization (EER) is linked with idiopathic ventricular fibrillation in adults. It is frequently seen in children, with poorly understood significance. Some evidence suggests that it could be a vagally mediated phenomenon. A retrospective case-control study was undertaken to test the hypothesis that EER is more common among children with typical vasovagal syncope (VVS) than among their peers with nonvagal syncope (NVS) or with no syncope., Methods: Patients aged 4-18 years with syncope were identified by a single-centre database search followed by a review of history for features of VVS (n = 150) or NVS (n = 84). The first available electrocardiogram (ECG) for VVS or for NVS was retrieved. Age- and sex-matched children with no known syncope or heart disease were then identified (n = 216). ECGs were assessed separately for EER based on published criteria by 2 observers blinded to patients' clinical status., Results: Mean age was 12.3 ± 3.2 years, and heart rate was 74.2 ± 16.5 beats/min. EER was more prevalent in VVS (33.3%) than among patients with NVS (19.1%; odds ratio: 2.29; confidence interval: 1.32-5.50) or among those with no syncope (12.5%; odds ratio: 3.14; confidence interval: 1.81-5.46). Heart rates were significantly lower in VVS and NVS (heart rate: 70.1 ± 13.8 and 70.7 ± 12.4 beats/min, respectively) compared with children with no syncope (heart rate: 78.2 ± 18.0 beats/min), both P < 0.001., Conclusions: EER is more common in paediatric patients with VVS than those with NVS or without syncope, consistent with a possible vagal contribution to the ECG finding., (© 2023 The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
21. Reconstruction of shear wave speed in tissue-mimicking phantoms from aliased pulse-echo imaging of high-frequency wavefields.
- Author
-
Dayavansha EGS, Gross GJ, Ehrman MC, Grimm PD, and Mast TD
- Subjects
- Elasticity, Phantoms, Imaging, Signal-To-Noise Ratio, Sound, Elasticity Imaging Techniques methods
- Abstract
Quantitative elasticity estimation in medical and industrial applications may benefit from advancements in reconstruction of shear wave speed with enhanced resolution. Here, shear wave speed is reconstructed from pulse-echo ultrasound imaging of elastic waves induced by high-frequency (>400 Hz), time-harmonic mechanical excitation. Particle displacement in shear wavefields is mapped from measured interframe phase differences with compensation for timing of multiple scan lines, then processed by spatial Fourier analysis to estimate the predominant wave speed and analyzed by algebraic wavefield inversion to reconstruct wave speed maps. Reconstructions of shear wave speed from simulated wavefields illustrate the accuracy and spatial resolution available with both methods, as functions of signal-to-noise ratio and sizes of windows used for Fourier analysis or wavefield smoothing. The methods are applied to shear wavefields with frequencies up to six times the Nyquist rate, thus extending the frequency range measurable by a given imaging system. Wave speed measurements in tissue-mimicking phantoms are compared with supersonic shear imaging and mechanical tensile testing, demonstrating feasibility of the wavefield measurement and wave speed reconstruction methods employed.
- Published
- 2021
- Full Text
- View/download PDF
22. Rare haematogenous sarcoma metastasis to the heart in a child - ERRATUM.
- Author
-
Gross GJ, Postovsky S, and Khoury A
- Published
- 2019
- Full Text
- View/download PDF
23. Epoxyeicosatrienoic acid analog EET-B attenuates post-myocardial infarction remodeling in spontaneously hypertensive rats.
- Author
-
Neckář J, Hye Khan MA, Gross GJ, Cyprová M, Hrdlička J, Kvasilová A, Falck JR, Campbell WB, Sedláková L, Škutová Š, Olejníčková V, Gregorovičová M, Sedmera D, Kolář F, and Imig JD
- Subjects
- Animals, Arachidonic Acids chemistry, Blood Pressure, Disease Models, Animal, Heart physiopathology, Heme Oxygenase-1 genetics, Heme Oxygenase-1 metabolism, Humans, Male, Myocardial Infarction genetics, Myocardial Infarction metabolism, Myocardial Infarction physiopathology, Rats, Rats, Inbred SHR, Arachidonic Acids administration & dosage, Myocardial Infarction drug therapy
- Abstract
Epoxyeicosatrienoic acids (EETs) and their synthetic analogs have cardiovascular protective effects. Here, we investigated the action of a novel EET analog EET-B on the progression of post-myocardial infarction (MI) heart failure in spontaneously hypertensive rats (SHR). Adult male SHR were divided into vehicle- and EET-B (10 mg/kg/day; p.o., 9 weeks)-treated groups. After 2 weeks of treatment, rats were subjected to 30-min left coronary artery occlusion or sham operation. Systolic blood pressure (SBP) and echocardiography (ECHO) measurements were performed at the beginning of study, 4 days before, and 7 weeks after MI. At the end of the study, tissue samples were collected for histological and biochemical analyses. We demonstrated that EET-B treatment did not affect blood pressure and cardiac parameters in SHR prior to MI. Fractional shortening (FS) was decreased to 18.4 ± 1.0% in vehicle-treated MI rats compared with corresponding sham (30.6 ± 1.0%) 7 weeks following MI induction. In infarcted SHR hearts, EET-B treatment improved FS (23.7 ± 0.7%), markedly increased heme oxygenase-1 (HO-1) immunopositivity in cardiomyocytes and reduced cardiac inflammation and fibrosis (by 13 and 19%, respectively). In conclusion, these findings suggest that EET analog EET-B has beneficial therapeutic actions to reduce cardiac remodeling in SHR subjected to MI., (© 2019 The Author(s). Published by Portland Press Limited on behalf of the Biochemical Society.)
- Published
- 2019
- Full Text
- View/download PDF
24. Ticagrelor for Refractory Migraine/Patent Foramen Ovale (TRACTOR): An open-label pilot study.
- Author
-
Reisman AM, Robbins BT, Chou DE, Yugrakh MS, Gross GJ, Privitera L, Nazif T, and Sommer RJ
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Pilot Projects, Foramen Ovale, Patent complications, Migraine Disorders complications, Migraine Disorders drug therapy, Platelet Aggregation Inhibitors therapeutic use, Ticagrelor therapeutic use
- Abstract
Objective: After finding that the thienopyridines clopidogrel and prasugrel reduced migraine headache (MHA) symptoms in some patients with patent foramen ovale (PFO), this small pilot study was undertaken to determine whether ticagrelor, a nonthienopyridine P2Y12 inhibitor, would have similar MHA effects and might be better suited for a future randomized trial., Methods: MHA patients were screened for PFO. Participants with documented right to left shunt (RLS) and ≥6 monthly MHA days received ticagrelor therapy for 28 days. Those with ≥50% reduction in monthly MHA days were deemed responders and completed 2 additional treatment months., Results: The 40 participants had a mean age of 36.2 years and mean MHA frequency of 17.4 d/mo. A total of 39/40 were female. A total of 14/40 met criteria for episodic MHA, 26/40 for chronic MHA, 14/40 had migraine with aura, and 22/40 had a moderate-large RLS (Spencer grade ≥4). Seventeen of 40 participants (43%) were responders. MHA reduction continued through 3 treatment months in all responders. MHA responder rates were not statistically different in participants with episodic or chronic MHA, with or without aura, or with small/larger RLS shunt magnitude. Thirteen (32%) patients had medication side effects, without serious adverse events., Conclusion: P2Y12 inhibition with ticagrelor reduced MHA symptoms similarly to our previous thienopyridine experience, but participants seemed to have a less robust MHA benefit and more frequent side effects than with the thienopyridines, making it an inferior choice for a randomized trial., Classification of Evidence: This study provides Class IV evidence that ticagrelor reduced MHA symptoms in patients with PFO., (© 2018 American Academy of Neurology.)
- Published
- 2018
- Full Text
- View/download PDF
25. Infarct size-limiting effect of epoxyeicosatrienoic acid analog EET-B is mediated by hypoxia-inducible factor-1α via downregulation of prolyl hydroxylase 3.
- Author
-
Neckář J, Hsu A, Hye Khan MA, Gross GJ, Nithipatikom K, Cyprová M, Benák D, Hlaváčková M, Sotáková-Kašparová D, Falck JR, Sedmera D, Kolář F, and Imig JD
- Subjects
- 8,11,14-Eicosatrienoic Acid analogs & derivatives, 8,11,14-Eicosatrienoic Acid therapeutic use, Animals, Disease Models, Animal, Down-Regulation, Hypoxia-Inducible Factor 1, alpha Subunit genetics, Hypoxia-Inducible Factor-Proline Dioxygenases genetics, Male, Myocardial Infarction enzymology, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Myocardial Reperfusion Injury enzymology, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Myocardium pathology, Proteolysis, Rats, Sprague-Dawley, Signal Transduction drug effects, 8,11,14-Eicosatrienoic Acid pharmacology, Hypoxia-Inducible Factor 1, alpha Subunit metabolism, Hypoxia-Inducible Factor-Proline Dioxygenases metabolism, Myocardial Infarction prevention & control, Myocardial Reperfusion Injury prevention & control, Myocardium enzymology, Ventricular Function, Left drug effects, Ventricular Remodeling drug effects
- Abstract
Epoxyeicosatrienoic acids (EETs) decrease cardiac ischemia-reperfusion injury; however, the mechanism of their protective effect remains elusive. Here, we investigated the cardioprotective action of a novel EET analog, EET-B, in reperfusion and the role of hypoxia-inducible factor (HIF)-1α in such action of EET-B. Adult male rats were subjected to 30 min of left coronary artery occlusion followed by 2 h of reperfusion. Administration of 14,15-EET (2.5 mg/kg) or EET-B (2.5 mg/kg) 5 min before reperfusion reduced infarct size expressed as a percentage of the area at risk from 64.3 ± 1.3% in control to 42.6 ± 1.9% and 46.0 ± 1.6%, respectively, and their coadministration did not provide any stronger effect. The 14,15-EET antagonist 14,15-epoxyeicosa-5( Z)-enoic acid (2.5 mg/kg) inhibited the infarct size-limiting effect of EET-B (62.5 ± 1.1%). Similarly, the HIF-1α inhibitors 2-methoxyestradiol (2.5 mg/kg) and acriflavine (2 mg/kg) completely abolished the cardioprotective effect of EET-B. In a separate set of experiments, the immunoreactivity of HIF-1α and its degrading enzyme prolyl hydroxylase domain protein 3 (PHD3) were analyzed in the ischemic areas and nonischemic septa. At the end of ischemia, the HIF-1α immunogenic signal markedly increased in the ischemic area compared with the septum (10.31 ± 0.78% vs. 0.34 ± 0.08%). After 20 min and 2 h of reperfusion, HIF-1α immunoreactivity decreased to 2.40 ± 0.48% and 1.85 ± 0.43%, respectively, in the controls. EET-B blunted the decrease of HIF-1α immunoreactivity (7.80 ± 0.69% and 6.44 ± 1.37%, respectively) and significantly reduced PHD3 immunogenic signal in ischemic tissue after reperfusion. In conclusion, EET-B provides an infarct size-limiting effect at reperfusion that is mediated by HIF-1α and downregulation of its degrading enzyme PHD3. NEW & NOTEWORTHY The present study shows that EET-B is an effective agonistic 14,15-epoxyeicosatrienoic acid analog, and its administration before reperfusion markedly reduced myocardial infarction in rats. Most importantly, we demonstrate that increased hypoxia-inducible factor-1α levels play a role in cardioprotection mediated by EET-B in reperfusion likely by mechanisms including downregulation of the hypoxia-inducible factor -1α-degrading enzyme prolyl hydroxylase domain protein 3.
- Published
- 2018
- Full Text
- View/download PDF
26. Transient receptor potential vanilloid 1 inhibitors block laparotomy- and opioid-induced infarct size reduction in rats.
- Author
-
Heymann HM, Wu Y, Lu Y, Qvit N, Gross GJ, and Gross ER
- Subjects
- Animals, Capsaicin chemistry, Capsaicin pharmacology, Male, Myocardial Infarction pathology, Rats, Rats, Sprague-Dawley, Analgesics, Opioid pharmacology, Capsaicin analogs & derivatives, Myocardial Infarction drug therapy, Myocardial Infarction surgery, Pyridines pharmacology, TRPV Cation Channels antagonists & inhibitors
- Abstract
Background and Purpose: In light of the opioid epidemic, physicians are increasingly prescribing non-opioid analgesics to surgical patients. Transient receptor potential vanilloid 1 (TRPV1) inhibitors are potentially alternative pain therapeutics for surgery. Here, we examined in rodents whether the cardioprotection conferred by two common procedures during surgery, a laparotomy or morphine delivery, is mediated by the TRPV1 channel. We further tested whether an experimental analgesic peptide (known as P5) targeted against the TRPV1 C-terminus region interferes with laparotomy- or morphine-induced cardioprotection., Experimental Approach: Male Sprague-Dawley rats were subjected to 30 min coronary occlusion followed by 120 min reperfusion. Before ischaemia, a laparotomy with or without capsaicin application (0.1% cream, a TRPV1 activator) was performed. Additional rats were given morphine (0.3 mg·kg
-1 ) with or without capsaicin. In addition, capsazepine (3 mg·kg-1 , a classical TRPV1 inhibitor), or P5 (3 mg·kg-1 , a peptide analgesic and TRPV1 inhibitor), was given either alone or prior to a laparotomy or morphine administration. Myocardial infarct size was determined., Key Results: A laparotomy, in addition to combining a laparotomy with capsaicin cream, reduced infarct size versus control. Morphine, in addition to combining morphine administration with capsaicin cream, also reduced infarct size versus control. When TRPV1 inhibitors capsazepine or P5 were given, either TRPV1 inhibitor abolished the infarct size reduction mediated by a laparotomy or morphine., Conclusions and Implications: Inhibiting the TRPV1 channel blocks laparotomy- or morphine-induced cardioprotection. Impaired organ protection may be a potential pitfall of using TRPV1 inhibitors for pain control., (© 2017 The British Pharmacological Society.)- Published
- 2017
- Full Text
- View/download PDF
27. A novel fibroblast growth factor-1 ligand with reduced heparin binding protects the heart against ischemia-reperfusion injury in the presence of heparin co-administration.
- Author
-
Huang C, Liu Y, Beenken A, Jiang L, Gao X, Huang Z, Hsu A, Gross GJ, Wang YG, Mohammadi M, and Schultz JEJ
- Subjects
- Animals, Cardiovascular Agents metabolism, Cardiovascular Agents pharmacokinetics, Disease Models, Animal, Extracellular Signal-Regulated MAP Kinases metabolism, Fibroblast Growth Factor 1 genetics, Fibroblast Growth Factor 1 metabolism, Fibroblast Growth Factor 1 pharmacokinetics, Heparin metabolism, Humans, Ligands, Male, Mutation, Myocardial Contraction drug effects, Myocardial Infarction metabolism, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Myocardium pathology, Protein Binding, Rats, Sprague-Dawley, Receptor, Fibroblast Growth Factor, Type 1 metabolism, Recovery of Function, Tissue Distribution, Ventricular Function, Left drug effects, Cardiovascular Agents pharmacology, Fibroblast Growth Factor 1 pharmacology, Heparin pharmacology, Myocardial Infarction prevention & control, Myocardial Reperfusion Injury prevention & control, Myocardium metabolism
- Abstract
Aims: Fibroblast growth factor 1 (FGF1), a heparin/heparan sulfate-binding growth factor, is a potent cardioprotective agent against myocardial infarction (MI). The impact of heparin, the standard of care for MI patients entering the emergency room, on cardioprotective effects of FGF1 is unknown, however., Methods and Results: To address this, a rat model of MI was employed to compare cardioprotective potentials (lower infarct size and improve post-ischemic function) of native FGF1 and an engineered FGF1 (FGF1ΔHBS) with reduced heparin-binding affinity when given at the onset of reperfusion in the absence or presence of heparin. FGF1 and FGF1ΔHBS did not alter heparin's anticoagulant properties. Treatment with heparin alone or native FGF1 significantly reduced infarct size compared to saline (P < 0.05). Surprisingly, treatment with FGF1ΔHBS markedly lowered infarct size compared to FGF1 (P < 0.05). Both native and modified FGF1 restored contractile and relaxation function (P < 0.05 versus saline or heparin). Furthermore, FGF1ΔHBS had greater improvement in cardiac function compared to FGF1 (P < 0.05). Heparin negatively impacted the cardioprotective effects (infarct size, post-ischemic recovery of function) of FGF1 (P < 0.05) but not of FGF1ΔHBS. Heparin also reduced the biodistribution of FGF1, but not FGF1ΔHBS, to the left ventricle. FGF1 and FGF1ΔHBS bound and triggered FGFR1-induced downstream activation of ERK1/2 (P < 0.05); yet, heparin co-treatment decreased FGF1-produced ERK1/2 activation, but not that activated by FGF1ΔHBS., Conclusion: These findings demonstrate that modification of the heparin-binding region of FGF1 significantly improves the cardioprotective efficacy, even in the presence of heparin, identifying a novel FGF ligand available for therapeutic use in ischemic heart disease., (Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2017. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2017
- Full Text
- View/download PDF
28. External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy.
- Author
-
Chou DE, Gross GJ, Casadei CH, and Yugrakh MS
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Prospective Studies, Treatment Outcome, Migraine Disorders therapy, Pain Management methods, Transcutaneous Electric Nerve Stimulation methods, Trigeminal Nerve
- Abstract
Objective: The aim of the current study is to assess the safety and efficacy of external trigeminal nerve stimulation (e-TNS) via a transcutaneous supraorbital stimulator as an acute treatment for migraine attacks., Materials and Methods: This was a prospective, open-labeled clinical trial conducted at the Columbia University Headache Center (NY, USA). Thirty patients who were experiencing an acute migraine attack with or without aura were treated with a one-hour session of e-TNS (CEFALY Technology) at the clinic. Pain intensity was scored using a visual analogue scale (VAS) before the treatment, after the one-hour treatment session, and at two hours after treatment initiation. Rescue migraine medication intake was recorded at 2 and 24 hours., Results: Thirty patients were included in the intention-to-treat analysis. Mean pain intensity was significantly reduced by 57.1% after the one-hour e-TNS treatment (-3.22 ± 2.40; p < 0.001) and by 52.8% at two hours (-2.98 ± 2.31; p < 0.001). No patients took rescue medication within the two-hour observation phase. Within the 24-hour follow-up, 34.6% of patients used a rescue medication. No adverse events or subjective complaints were reported., Conclusions: The findings from this open-labeled study suggest that transcutaneous supraorbital neurostimulation may be a safe and effective acute treatment for migraine attacks, and merits further study with a double-blind, randomized, sham-controlled trial., (© 2017 International Neuromodulation Society.)
- Published
- 2017
- Full Text
- View/download PDF
29. Cardiac findings in children with juvenile Dermatomyositis at disease presentation.
- Author
-
Cantez S, Gross GJ, MacLusky I, and Feldman BM
- Subjects
- Adolescent, Age of Onset, Canada epidemiology, Child, Child, Preschool, Echocardiography methods, Echocardiography statistics & numerical data, Electrocardiography methods, Electrocardiography statistics & numerical data, Female, Humans, Male, Mass Screening, Prognosis, Statistics as Topic, Dermatomyositis complications, Dermatomyositis diagnosis, Dermatomyositis epidemiology, Dermatomyositis physiopathology, Heart Diseases diagnosis, Heart Diseases epidemiology, Heart Diseases etiology
- Abstract
Background: Juvenile Dermatomyositis (JDM) is a pediatric vasculopathy characterized primarily by skin and muscle involvement. Cardiac findings have been reported in children with JDM but have rarely been investigated in detail., Methods: We aimed to describe the relevant clinical and laboratory cardiac findings of a cohort of patients with JDM, followed at one centre, at disease diagnosis., Results: We performed a retrospective review of 105 patients with JDM, followed from 1991 to 2007. Six of 70 patients (9%, 6% of the entire cohort) had abnormal electrocardiographic (ECG) findings, while 26 of 54 patients (48%, 25% of the entire cohort) had abnormal echocardiographic (echo) findings. Many of these findings were either mild or unlikely to be a result of JDM., Conclusions: Our findings suggest that cardiac abnormalities at JDM disease onset are frequently seen, but are rarely significant findings due to disease; however, JDM patients should be considered for screening for cardiac disease as late cardiac complications are well recognized.
- Published
- 2017
- Full Text
- View/download PDF
30. Transient Receptor Potential Vanilloid 1 Regulates Mitochondrial Membrane Potential and Myocardial Reperfusion Injury.
- Author
-
Hurt CM, Lu Y, Stary CM, Piplani H, Small BA, Urban TJ, Qvit N, Gross GJ, Mochly-Rosen D, and Gross ER
- Abstract
Background: The transient receptor potential vanilloid 1 (TRPV1) mediates cellular responses to pain, heat, or noxious stimuli by calcium influx; however, the cellular localization and function of TRPV1 in the cardiomyocyte is largely unknown. We studied whether myocardial injury is regulated by TRPV1 and whether we could mitigate reperfusion injury by limiting the calcineurin interaction with TRPV1., Methods and Results: In primary cardiomyocytes, confocal and electron microscopy demonstrates that TRPV1 is localized to the mitochondria. Capsaicin, the specific TRPV1 agonist, dose-dependently reduced mitochondrial membrane potential and was blocked by the TRPV1 antagonist capsazepine or the calcineurin inhibitor cyclosporine. Using in silico analysis, we discovered an interaction site for TRPV1 with calcineurin. We synthesized a peptide, V1-cal, to inhibit the interaction between TRPV1 and calcineurin. In an in vivo rat myocardial infarction model, V1-cal given just prior to reperfusion substantially mitigated myocardial infarct size compared with vehicle, capsaicin, or cyclosporine (24±3% versus 61±2%, 45±1%, and 49±2%, respectively; n=6 per group; P<0.01 versus all groups). Infarct size reduction by V1-cal was also not seen in TRPV1 knockout rats., Conclusions: TRPV1 is localized at the mitochondria in cardiomyocytes and regulates mitochondrial membrane potential through an interaction with calcineurin. We developed a novel therapeutic, V1-cal, that substantially reduces reperfusion injury by inhibiting the interaction of calcineurin with TRPV1. These data suggest that TRPV1 is an end-effector of cardioprotection and that modulating the TRPV1 protein interaction with calcineurin limits reperfusion injury., (© 2016 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley Blackwell.)
- Published
- 2016
- Full Text
- View/download PDF
31. Intestinal Microbial Metabolites Are Linked to Severity of Myocardial Infarction in Rats.
- Author
-
Lam V, Su J, Hsu A, Gross GJ, Salzman NH, and Baker JE
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Metabolomics, Phenotype, Rats, Vancomycin pharmacology, Gastrointestinal Microbiome drug effects, Myocardial Infarction metabolism, Myocardial Infarction microbiology
- Abstract
Intestinal microbiota determine severity of myocardial infarction in rats. We determined whether low molecular weight metabolites derived from intestinal microbiota and transported to the systemic circulation are linked to severity of myocardial infarction. Plasma from rats treated for seven days with the non-absorbed antibiotic vancomycin or a mixture of streptomycin, neomycin, polymyxin B and bacitracin was analyzed using mass spectrometry-based metabolite profiling platforms. Antibiotic-induced changes in the abundance of individual groups of intestinal microbiota dramatically altered the host's metabolism. Hierarchical clustering of dissimilarities separated the levels of 284 identified metabolites from treated vs. untreated rats; 193 were altered by the antibiotic treatments with a tendency towards decreased metabolite levels. Catabolism of the aromatic amino acids phenylalanine, tryptophan and tyrosine was the most affected pathway comprising 33 affected metabolites. Both antibiotic treatments decreased the severity of an induced myocardial infarction in vivo by 27% and 29%, respectively. We then determined whether microbial metabolites of the amino acids phenylalanine, tryptophan and tyrosine were linked to decreased severity of myocardial infarction. Vancomycin-treated rats were administered amino acid metabolites prior to ischemia/reperfusion studies. Oral or intravenous pretreatment of rats with these amino acid metabolites abolished the decrease in infarct size conferred by vancomycin. Inhibition of JAK-2 (AG-490, 10 μM), Src kinase (PP1, 20 μM), Akt/PI3 kinase (Wortmannin, 100 nM), p44/42 MAPK (PD98059, 10 μM), p38 MAPK (SB203580, 10 μM), or KATP channels (glibenclamide, 3 μM) abolished cardioprotection by vancomycin, indicating microbial metabolites are interacting with cell surface receptors to transduce their signals through Src kinase, cell survival pathways and KATP channels. These inhibitors have no effect on myocardial infarct size in untreated rats. This study links gut microbiota metabolites to severity of myocardial infarction and may provide future opportunities for novel diagnostic tests and interventions for the prevention of cardiovascular disease.
- Published
- 2016
- Full Text
- View/download PDF
32. Thrombopoietin receptor agonists protect human cardiac myocytes from injury by activation of cell survival pathways.
- Author
-
Baker JE, Su J, Koprowski S, Dhanasekaran A, Aufderheide TP, and Gross GJ
- Subjects
- Cell Hypoxia drug effects, Cell Hypoxia physiology, Cell Survival drug effects, Cell Survival physiology, Cells, Cultured, Dose-Response Relationship, Drug, Humans, Myocytes, Cardiac drug effects, Proto-Oncogene Mas, Signal Transduction drug effects, Thrombopoietin pharmacology, Benzoates pharmacology, Cardiotonic Agents pharmacology, Hydrazines pharmacology, Myocytes, Cardiac physiology, Pyrazoles pharmacology, Receptors, Thrombopoietin agonists, Receptors, Thrombopoietin physiology, Signal Transduction physiology
- Abstract
Thrombopoietin confers immediate protection against injury caused by ischemia/reperfusion in the rat heart. Eltrombopag is a small molecule agonist of the thrombopoietin receptor, the physiologic target of thrombopoietin. However, the ability of eltrombopag and thrombopoietin to protect human cardiac myocytes against injury and the mechanisms underlying myocyte protection are not known. Human cardiac myocytes (n = 6-10/group) were treated with eltrombopag (0.1-30.0 µM) or thrombopoietin (0.1-30.0 ng/ml) and then subjected to 5 hours of hypoxia (95% N2/5% CO2) and 16 hours of reoxygenation to determine their ability to confer resistance to myocardial injury. The thrombopoietin receptor c-Mpl was detected in unstimulated human cardiac myocytes by Western blotting. Eltrombopag and thrombopoietin confer immediate protection to human cardiac myocytes against injury from hypoxia/reoxygenation by decreasing necrotic and apoptotic cell death in a concentration-dependent manner, with an optimal concentration of 3 µM for eltrombopag and 1.0 ng/ml for thrombopoietin. The extent of protection conferred with eltrombopag is equivalent to that of thrombopoietin. Eltrombopag and thrombopoietin activate multiple prosurvival pathways; inhibition of Janus kinase-2, proto-oncogene tyrosine-protein kinase, protein kinase B/phosphatidylinositol-3 kinase, p44/42 mitogen-activated protein kinase (MAPK), and p38 MAPK abolished cardiac myocyte protection by eltrombopag and thrombopoietin. Eltrombopag and thrombopoietin may represent important and potent agents for immediately and substantially increasing protection of human cardiac myocytes, and may offer a long-lasting benefit through activation of prosurvival pathways during ischemia., (Copyright © 2015 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2015
- Full Text
- View/download PDF
33. Morphine Reduces Myocardial Infarct Size via Heat Shock Protein 90 in Rodents.
- Author
-
Small BA, Lu Y, Hsu AK, Gross GJ, and Gross ER
- Subjects
- Amino Acid Sequence, Animals, Glycogen Synthase Kinase 3 metabolism, Glycogen Synthase Kinase 3 beta, Male, Molecular Sequence Data, Myocardial Infarction pathology, Myocardium pathology, Rats, Rats, Sprague-Dawley, HSP90 Heat-Shock Proteins metabolism, Heart drug effects, Morphine pharmacology, Myocardial Infarction metabolism
- Abstract
Opioids reduce injury from myocardial ischemia-reperfusion in humans. In experimental models, this mechanism involves GSK3β inhibition. HSP90 regulates mitochondrial protein import, with GSK3β inhibition increasing HSP90 mitochondrial content. Therefore, we determined whether morphine-induced cardioprotection is mediated by HSP90 and if the protective effect is downstream of GSK3β inhibition. Male Sprague-Dawley rats, aged 8-10 weeks, were subjected to an in vivo myocardial ischemia-reperfusion injury protocol involving 30 minutes of ischemia followed by 2 hours of reperfusion. Hemodynamics were continually monitored and myocardial infarct size determined. Rats received morphine (0.3 mg/kg), the GSK3β inhibitor, SB216763 (0.6 mg/kg), or saline, 10 minutes prior to ischemia. Some rats received selective HSP90 inhibitors, radicicol (0.3 mg/kg), or deoxyspergualin (DSG, 0.6 mg/kg) alone or 5 minutes prior to morphine or SB216763. Morphine reduced myocardial infarct size when compared to control (42 ± 2% versus 60 ± 1%). This protection was abolished by prior treatment of radicicol or DSG (59 ± 1%, 56 ± 2%). GSK3β inhibition also reduced myocardial infarct size (41 ± 2%) with HSP90 inhibition by radicicol or DSG partially inhibiting SB216763-induced infarct size reduction (54 ± 3%, 47 ± 1%, resp.). These data suggest that opioid-induced cardioprotection is mediated by HSP90. Part of this protection afforded by HSP90 is downstream of GSK3β, potentially via the HSP-TOM mitochondrial import pathway.
- Published
- 2015
- Full Text
- View/download PDF
34. Lone atrial fibrillation in the pediatric population.
- Author
-
Mills LC, Gow RM, Myers K, Kantoch MJ, Gross GJ, Fournier A, and Sanatani S
- Subjects
- Adolescent, Alberta epidemiology, Atrial Fibrillation physiopathology, Atrial Fibrillation therapy, British Columbia epidemiology, Female, Follow-Up Studies, Humans, Male, Morbidity trends, Ontario epidemiology, Quebec epidemiology, Recurrence, Retrospective Studies, Anti-Arrhythmia Agents therapeutic use, Atrial Fibrillation epidemiology, Catheter Ablation, Electric Countershock
- Abstract
Background: There are few reports of pediatric studies of atrial fibrillation (AF). We sought to describe the clinical characteristics, management strategies, and recurrence rates and to identify predictors of AF recurrence in a contemporary pediatric population., Methods: A retrospective review was performed of patients ≤ 18 years with lone AF who were seen at 4 pediatric institutions from 1996-2011. Patients with AF in the setting of thyroid disease, ventricular pre-excitation, coexisting congenital heart disease, or a history of cardiac surgery were excluded. Demographics, clinical presentation, investigations, treatment, and follow-up were analyzed., Results: Forty-two patients were diagnosed with a first episode of lone AF, and 4 of these cases were later classified as persistent AF. Thirty-one (74%) were male patients, median age was 15.3 years, and median (interquartile range [IQR]) duration of AF episode was 12 (IQR, 7-24) hours. AF recurred in 39% (15 of 38) of patients. The Kaplan-Meier median time to estimated recurrence was 19 months. By univariate analysis, initial AF episode duration was associated with a higher risk of recurrence (hazard ratio [HR], 1.01; 95% confidence interval [CI], 1-1.02; P = 0.034). Sex, age, family history, size of the left atrium, and history of cardioversion were not associated with recurrence. Recurrence with another supraventricular tachyarrhythmia (SVT) was observed in 6 of 38 (16%) patients, and 12 patients underwent electrophysiology (EP) study, with 6 patients receiving ablation., Conclusions: Our reported rate of recurrence of 39% is important when counseling pediatric patients and their parents on the expected course and treatment goals., (Copyright © 2013 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
35. Nociceptive-induced myocardial remote conditioning is mediated by neuronal gamma protein kinase C.
- Author
-
Gross ER, Hsu AK, Urban TJ, Mochly-Rosen D, and Gross GJ
- Subjects
- Animals, Blotting, Western, Disease Models, Animal, Male, Myocardial Reperfusion Injury prevention & control, Rats, Rats, Sprague-Dawley, Ischemic Preconditioning, Myocardial methods, Myocardial Reperfusion Injury metabolism, Pain physiopathology, Protein Kinase C metabolism
- Abstract
Deciphering the remote conditioning molecular mechanism may provide targets to develop therapeutics that can broaden the clinical application. To further investigate this, we tested whether two protein kinase C (PKC) isozymes, the ubiquitously expressed epsilon PKC (εPKC) and the neuronal-specific gamma PKC (γPKC), mediate nociceptive-induced remote myocardial conditioning. Male Sprague-Dawley rats were used for both in vivo and ex vivo myocardial ischemia-reperfusion protocols. For the in vivo studies, using a surgical abdominal incision for comparison, applying only to the abdomen either bradykinin or the εPKC activator (ψεRACK) reduced myocardial infarct size (45 ± 1, 44 ± 2 %, respectively, vs. incision: 43 ± 2 %, and control: 63 ± 2 %, P < 0.001). Western blot showed only εPKC, and not γPKC, is highly expressed in the myocardium. However, applying a selective γPKC inhibitor (γV5-3) to the abdominal skin blocked remote protection by any of these strategies. Using an ex vivo isolated heart model without an intact nervous system, only selective εPKC activation, unlike a selective classical PKC isozyme activator (activating α, β, βII, and γ), reduced myocardial injury. Importantly, the classical PKC isozyme activator given to the abdomen in vivo (with an intact nervous system including γPKC) during myocardial ischemia reduced infarct size as effectively as an abdominal incision or ψεRACK (45 ± 1 vs. 45 ± 2 and 47 ± 1 %, respectively). The classical PKC activator-induced protection was also blocked by spinal cord surgical transection. These findings identified potential remote conditioning mimetics, with these strategies effective even during myocardial ischemia. A novel mechanism of nociceptive-induced remote conditioning, involving γPKC, was also identified.
- Published
- 2013
- Full Text
- View/download PDF
36. Mutation location effect on severity of phenotype during exercise testing in type 1 long-QT syndrome: impact of transmembrane and C-loop location.
- Author
-
Laksman ZW, Hamilton RM, Chockalingam P, Ballantyne E, Stephenson EA, Gross GJ, Gula LJ, Klein GJ, Wilde AA, and Krahn AD
- Subjects
- Adolescent, Adult, Cell Membrane genetics, Cohort Studies, Female, Humans, Male, Middle Aged, Retrospective Studies, Romano-Ward Syndrome physiopathology, Young Adult, Exercise Test methods, KCNQ1 Potassium Channel genetics, Mutation, Missense genetics, Phenotype, Romano-Ward Syndrome diagnosis, Romano-Ward Syndrome genetics
- Abstract
Background: Targeted mutation site-specific differences have correlated C-loop missense mutations with worse outcomes and increased benefit of beta-blockers in LQT1. This observation has implicated the C-loop region as being mechanistically important in the altered response to sympathetic stimulation known to put patients with LQT1 at risk of syncope and sudden cardiac death., Objective: The objective of this study was to determine if there is mutation site-specific response to sympathetic stimulation and beta-blockers using exercise testing., Methods: This study is a retrospective review of LQT1 patients undergoing exercise testing at 3 academic referral centers., Results: A total of 123 patients (age 28 ± 17 years, 59 male) were studied including 34 patients (28%) with C-loop mutations. There were no significant differences in supine, standing, peak exercise and 1-minute recovery QTc duration between patients with C-loop mutations and patients with alternate mutation sites. In 37 patients that underwent testing on and off beta-blockers, beta-blocker use was associated with a significant reduction in supine, standing and peak exercise QTc. This difference was not seen in the small group of patients (7/37) with C-loop mutations. There was no difference in QTc at 1 and 4 minutes into recovery., Conclusions: Genetically confirmed LQT1 patients in this study cohort with C-loop mutations did not demonstrate the expected increase in QTc in response to exercise, or resultant response to beta-blocker. The apparent increased risk of cardiac events associated with C-loop mutation sites and the marked benefit received from beta-blocker therapy are not reflected by exercise-mediated effects on QTc in this study population., (© 2013 Wiley Periodicals, Inc.)
- Published
- 2013
- Full Text
- View/download PDF
37. Biowire: a platform for maturation of human pluripotent stem cell-derived cardiomyocytes.
- Author
-
Nunes SS, Miklas JW, Liu J, Aschar-Sobbi R, Xiao Y, Zhang B, Jiang J, Massé S, Gagliardi M, Hsieh A, Thavandiran N, Laflamme MA, Nanthakumar K, Gross GJ, Backx PH, Keller G, and Radisic M
- Subjects
- Cell Differentiation physiology, Electric Stimulation, Electrophysiological Phenomena, Humans, Microscopy, Electron, Transmission, Myocardium ultrastructure, Cell Culture Techniques methods, Induced Pluripotent Stem Cells cytology, Myocardium cytology, Myocytes, Cardiac cytology, Tissue Engineering methods
- Abstract
Directed differentiation protocols enable derivation of cardiomyocytes from human pluripotent stem cells (hPSCs) and permit engineering of human myocardium in vitro. However, hPSC-derived cardiomyocytes are reflective of very early human development, limiting their utility in the generation of in vitro models of mature myocardium. Here we describe a platform that combines three-dimensional cell cultivation with electrical stimulation to mature hPSC-derived cardiac tissues. We used quantitative structural, molecular and electrophysiological analyses to explain the responses of immature human myocardium to electrical stimulation and pacing. We demonstrated that the engineered platform allows for the generation of three-dimensional, aligned cardiac tissues (biowires) with frequent striations. Biowires submitted to electrical stimulation had markedly increased myofibril ultrastructural organization, elevated conduction velocity and improved both electrophysiological and Ca(2+) handling properties compared to nonstimulated controls. These changes were in agreement with cardiomyocyte maturation and were dependent on the stimulation rate.
- Published
- 2013
- Full Text
- View/download PDF
38. Roles of endothelial nitric oxide synthase (eNOS) and mitochondrial permeability transition pore (MPTP) in epoxyeicosatrienoic acid (EET)-induced cardioprotection against infarction in intact rat hearts.
- Author
-
Gross GJ, Hsu A, Pfeiffer AW, and Nithipatikom K
- Subjects
- 8,11,14-Eicosatrienoic Acid antagonists & inhibitors, 8,11,14-Eicosatrienoic Acid pharmacology, 8,11,14-Eicosatrienoic Acid therapeutic use, Animals, Cell Line, Hemodynamics physiology, Imines pharmacology, Male, Mitochondrial Permeability Transition Pore, Myocardial Infarction metabolism, Nitric Oxide metabolism, Nitric Oxide Synthase Type III antagonists & inhibitors, Rats, Rats, Sprague-Dawley, Reperfusion Injury drug therapy, Reperfusion Injury enzymology, Reperfusion Injury metabolism, 8,11,14-Eicosatrienoic Acid analogs & derivatives, Heart drug effects, Mitochondrial Membrane Transport Proteins drug effects, Mitochondrial Membrane Transport Proteins metabolism, Myocardial Infarction enzymology, Myocardial Infarction prevention & control, Nitric Oxide Synthase Type III metabolism
- Abstract
We previously demonstrated that 11,12 and 14,15-epoxeicosatrienoic acids (EETs) produce cardioprotection against ischemia-reperfusion injury in dogs and rats. Several signaling mechanisms have been implicated in the cardioprotective actions of the EETs; however, their mechanisms remain largely elusive. Since nitric oxide (NO) plays a significant role in cardioprotection and EETs have been demonstrated to induce NO production in various tissues, we hypothesized that NO is involved in mediating the EET actions in cardioprotection. To test this hypothesis, we used an in vivo rat model of infarction in which intact rat hearts were subjected to 30-min occlusion of the left coronary artery and 2-hr reperfusion. 11,12-EET or 14,15-EET (2.5mg/kg) administered 10min prior to the occlusion reduced infarct size, expressed as a percentage of the AAR (IS/AAR), from 63.9±0.8% (control) to 45.3±1.2% and 45.5±1.7%, respectively. A nonselective nitric oxide synthase (NOS) inhibitor, L-NAME (1.0mg/kg) or a selective endothelial NOS inhibitor, L-NIO (0.30mg/kg) alone did not affect IS/AAR but they completely abolished the cardioprotective effects of the EETs. On the other hand, a selective neuronal NOS inhibitor, nNOS I (0.03mg/kg) and a selective inducible NOS inhibitor, 1400W (0.10mg/kg) did not affect IS/AAR or block the cardioprotective effects of the EETs. Administration of 11,12-EET (2.5mg/kg) to the rats also transiently increased the plasma NO concentration. 14,15-EET (10μM) induced the phosphorylation of eNOS (Ser(1177)) as well as a transient increase of NO production in rat cardiomyoblast cell line (H9c2 cells). When 11,12-EET or 14,15-EET was administered at 5min prior to reperfusion, infarct size was also reduced to 42.8±2.2% and 42.6±1.9%, respectively. Interestingly, L-NAME (1.0mg/kg) and a mitochondrial KATP channel blocker, 5-HD (10mg/kg) did not abolish while a sarcolemmal KATP channel blocker, HMR 1098 (6.0mg/kg) and a mitochondrial permeability transition pore (MPTP) opener, atractyloside (5.0mg/kg) completely abolished the cardioprotection produced by the EETs. 14,15-EET (1.5mg/kg) with an inhibitor of MPTP opening, cyclosporin A (CsA, 1.0mg/kg) produced a greater reduction of infarct size than their individual administration. Conversely, an EET antagonist 14,15-epoxyeicosa-5(Z)-enoic acid (14,15-EEZE, 2.5mg/kg) completely abolished the cardioprotective effects of CsA, suggesting a role of MPTP in mediating the EET actions. Taken together, these results suggest that the cardioprotective effects of the EETs in an acute ischemia-reperfusion model are mediated by distinct mediators depending on the time of EET administration. The cardioprotective effects of EETs administered prior to ischemia were regulated by the activation of eNOS and increased NO production, while sarcKATP channels and MPTP were involved in the beneficial effects of the EETs when administered just prior to reperfusion., (Copyright © 2012 Elsevier Ltd. All rights reserved.)
- Published
- 2013
- Full Text
- View/download PDF
39. Factors mediating remote preconditioning of trauma in the rat heart: central role of the cytochrome p450 epoxygenase pathway in mediating infarct size reduction.
- Author
-
Gross GJ, Hsu A, Gross ER, Falck JR, and Nithipatikom K
- Subjects
- 8,11,14-Eicosatrienoic Acid analogs & derivatives, 8,11,14-Eicosatrienoic Acid pharmacology, Animals, Capsaicin pharmacology, Hemodynamics, KATP Channels physiology, Male, Rats, Rats, Sprague-Dawley, Sarcolemma physiology, Xanthines pharmacology, Cytochrome P-450 Enzyme System physiology, Ischemic Preconditioning, Myocardial, Myocardial Infarction drug therapy
- Abstract
The present study further identified factors involved in the cardioprotective phenomenon of remote preconditioning of trauma (RPCT) with special emphasis on the role of the epoxyeicosatrienoic acids (EETs) in mediating this phenomenon. Remote preconditioning of trauma was produced by an abdominal incision only through the skin. Subsequently, all rats were subjected to 30 minutes of left coronary artery occlusion followed by 2 hours of reperfusion and the infarct size was determined. Remote preconditioning of trauma produced a reduction in infarct size expressed as a percentage of the area at risk from 63.0% ± 1.1% to 44.7% ± 1.4%; P < .01 versus control. To test the 3 major triggers of classical preconditioning in mediating RPCT, blockers of the bradykinin B2 receptor (B2BK), (S)-4-[2-[Bis(cyclohexylamino)methyleneamino]-3-(2-naphthalenyl)-1-oxopropylamino]benzyl tributyl phosphonium (WIN 64338, 1 mg/kg, iv), or HOE 140 (50 μg/kg, iv), the nonselective opioid receptor blocker, naloxone (3 mg/kg, iv), or the adenosine A1 receptor blocker, 8-Cyclopentyl-1,3-dipropylxanthine (DPCPX, 1 mg/kg, iv) were administered 10 minutes prior to RPCT. Only the 2 B2BK selective antagonists blocked RPCT (60.2% ± 1.1%, WIN 64338; 62.3% ± 2.0%, HOE 140). To test EETs in RPCT, we administered the EET receptor antagonist 14,15-Epoxyeicosa-5(Z)-enoic acid (14,15-EEZE, 2.5 mg/kg, iv) or the EET synthesis inhibitor, N-(Methylsulfonyl)-2-(2-propynyloxy)-benzenehexanamide (MSPPOH, 3.0 mg/kg, iv) 10 minutes prior to RPCT. In both groups, the EET antagonists completely blocked RPCT (62.0% ± 0.8%, 14,15-EEZE; 61.8% ± 1.0%, MSPPOH). The EET antagonists also blocked the effect of B2BK activation. We also determined whether the sarcolemmal K(ATP) or the mitochondrial K(ATP) channel mediate RPCT by pretreating rats with 1-[5-[2-(5-Chloro-o-anisamido)ethyl]-2-methoxyphenyl]sulfonyl-3 methylthiourea, sodium salt (HMR 1098) or 5-hydroxydecanoic acid (5-HD), respectively. Interestingly, 5-HD blocked RPCT (64.7% ± 1.3%), whereas, HMR 1098 did not (50.3% ± 1.3%). The 2 EET antagonists completely blocked capsaicin-induced cardioprotection. These results clearly suggest that EETs mediate RPCT-, bradykinin- and capsaicin-induced cardioprotection in rat hearts.
- Published
- 2013
- Full Text
- View/download PDF
40. Intestinal microbiota determine severity of myocardial infarction in rats.
- Author
-
Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman NH, and Baker JE
- Subjects
- Animals, Anti-Bacterial Agents pharmacology, Cytokines blood, Drinking Water, Humans, Intestines drug effects, Leptin blood, Leptin pharmacology, Myocardial Reperfusion Injury physiopathology, Probiotics therapeutic use, Rats, Rats, Inbred Dahl, Vancomycin pharmacology, Intestines microbiology, Metagenome drug effects, Myocardial Infarction pathology, Myocardial Infarction physiopathology, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury prevention & control
- Abstract
Signals from the intestinal microbiota are important for normal host physiology; alteration of the microbiota (dysbiosis) is associated with multiple disease states. We determined the effect of antibiotic-induced intestinal dysbiosis on circulating cytokine levels and severity of ischemia/reperfusion injury in the heart. Treatment of Dahl S rats with a minimally absorbed antibiotic vancomycin, in the drinking water, decreased circulating leptin levels by 38%, resulted in smaller myocardial infarcts (27% reduction), and improved recovery of postischemic mechanical function (35%) as compared with untreated controls. Vancomycin altered the abundance of intestinal bacteria and fungi, measured by 16S and 18S ribosomal DNA quantity. Pretreatment with leptin (0.12 μg/kg i.v.) 24 h before ischemia/reperfusion abolished cardioprotection produced by vancomycin treatment. Dahl S rats fed the commercially available probiotic product Goodbelly, which contains the leptin-suppressing bacteria Lactobacillus plantarum 299v, also resulted in decreased circulating leptin levels by 41%, smaller myocardial infarcts (29% reduction), and greater recovery of postischemic mechanical function (23%). Pretreatment with leptin (0.12 μg/kg i.v.) abolished cardioprotection produced by Goodbelly. This proof-of-concept study is the first to identify a mechanistic link between changes in intestinal microbiota and myocardial infarction and demonstrates that a probiotic supplement can reduce myocardial infarct size.
- Published
- 2012
- Full Text
- View/download PDF
41. Eribis peptide 94 reduces infarct size in rat hearts via activation of centrally located μ opioid receptors.
- Author
-
Gross GJ, Hsu A, Nithipatikom K, Bobrova I, and Bissessar E
- Subjects
- Animals, Blood-Brain Barrier metabolism, Cardiotonic Agents administration & dosage, Cardiotonic Agents pharmacology, Enkephalins administration & dosage, Male, Myocardial Infarction pathology, Narcotic Antagonists administration & dosage, Rats, Rats, Sprague-Dawley, Receptors, Opioid, mu antagonists & inhibitors, Receptors, Opioid, mu metabolism, Enkephalins pharmacology, Myocardial Infarction drug therapy, Narcotic Antagonists pharmacology, Receptors, Opioid, mu agonists
- Abstract
Eribis peptide 94 (EP 94) is a novel enkephalin derivative that binds with high potency to μ and δ opioid receptors with less affinity for the κ opioid receptor. This compound has recently been shown to produce an acute reduction in myocardial infarct size in the anesthetized pig and rat partially via an endothelial nitric oxide synthase and KATP channel-dependent mechanism. EP 94 also was found to produce a chronic reduction in infarct size 24 hours postdrug administration via the upregulation of inducible nitric oxide synthase in rats. Despite these findings, no data have emerged in which the opioid receptor subtype responsible for cardioprotection has been identified and the site of action, heart, other peripheral organs, or the central nervous system, has not been addressed. In the current study, EP 94, was administered in 2 divided doses (0.5 μg/kg, intravenously) at 5 and 10 minutes into the ischemic period, and the opioid antagonists were administered 10 minutes before the onset of the 30-minute ischemic period. The selective antagonists used were the μ receptor antagonist CTOP (D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2), the δ receptor antagonists naltrindole and BNTX (7-benzylidenenaltrexone), and the κ receptor antagonist nor-BNI (norbinaltorphimine). Surprisingly, only CTOP completely blocked the cardioprotective effect of EP 94, whereas naltrindole, BNTX, and nor-BNI had modest but nonsignificant effects. Because there is controversial evidence suggesting that μ receptors may be absent in the adult rat myocardium, it was hypothesized that the protective effect of EP 94 may be mediated by an action outside the heart, perhaps in the central nervous system. To test this hypothesis, rats were pretreated with the nonselective opioid antagonist, naloxone hydrochloride, which penetrates the blood-brain barrier or naloxone methiodide, the quaternary salt of naloxone hydrochloride, which does not penetrate the blood-brain barrier before EP 94 administration. In support of a central nervous system site of action for EP 94, naloxone hydrochloride completely blocked its cardioprotective effect, whereas naloxone methiodide had no effect. These results suggest that EP 94 reduces infarct size (expressed as a percent of the area at risk) in the rat primarily via activation of central μ opioid receptors.
- Published
- 2012
- Full Text
- View/download PDF
42. Dose-dependent cardioprotection of enkephalin analogue Eribis peptide 94 and cardiac expression of opioid receptors in a porcine model of ischaemia and reperfusion.
- Author
-
Karlsson LO, Bergh N, Li L, Bissessar E, Bobrova I, Gross GJ, Akyürek LM, and Grip L
- Subjects
- Animals, Arrhythmias, Cardiac complications, Arrhythmias, Cardiac drug therapy, Cardiotonic Agents blood, Cardiotonic Agents therapeutic use, Disease Models, Animal, Dose-Response Relationship, Drug, Enkephalins blood, Enkephalins therapeutic use, Female, Hemodynamics drug effects, Myocardial Infarction complications, Myocardial Infarction drug therapy, Myocardial Infarction pathology, Myocardial Ischemia metabolism, Myocardial Ischemia pathology, Myocardial Ischemia physiopathology, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Myocardium pathology, RNA, Messenger genetics, RNA, Messenger metabolism, Receptors, Opioid genetics, Risk, Swine, Cardiotonic Agents pharmacology, Enkephalins pharmacology, Gene Expression Regulation drug effects, Myocardial Ischemia drug therapy, Myocardial Reperfusion Injury drug therapy, Myocardium metabolism, Receptors, Opioid metabolism
- Abstract
Opioids confer cardioprotection after myocardial ischaemia and reperfusion. The primary aim of the present study was to evaluate the cardioprotective effect of different doses of enkephalin analogue Eribis peptide 94 (EP 94) in a porcine model of ischaemia and reperfusion. A secondary aim was to analyse the impact of ischaemia and reperfusion on the expression of opioid receptor subtypes in the porcine heart. Thirty-four anesthetised pigs underwent 40 min of balloon occlusion of the left anterior descending coronary artery followed by four hours of reperfusion. Pigs were given either vehicle (0.9% NaCl) or one of four doses of EP 94 (0.2, 1, 5 or 25 ug/kg at each administration, respectively), intravenously after 26, 33 and 40 min of ischaemia. Hearts were stained to quantify area at risk and infarct size. mRNA and protein expressions of the opioid receptor subtypes were detected with RT-PCR, immunoblotting and immunohistochemistry in the control and ischaemic/reperfused areas. There was a significant dose-response relationship between higher doses of EP 94 and reduced infarct size. Expression of κ- and δ-opioid receptors was detected at both mRNA and protein levels. In ischaemic/reperfused areas, an increased expression of mRNA for both receptors was observed, whereas only protein expression for the δ subtype was up-regulated. The μ-opioid receptor was not detected., (Copyright © 2011 Elsevier B.V. All rights reserved.)
- Published
- 2012
- Full Text
- View/download PDF
43. Acute and chronic cardioprotection by the enkephalin analogue, Eribis peptide 94, is mediated via activation of nitric oxide synthase and adenosine triphosphate-regulated potassium channels.
- Author
-
Gross GJ, Hsu A, Nithipatikom K, Pfeiffer AW, Bobrova I, and Bissessar E
- Subjects
- Animals, Benzamides pharmacology, Cardiotonic Agents pharmacology, Decanoic Acids pharmacology, Enkephalins pharmacology, Hydroxy Acids pharmacology, KATP Channels antagonists & inhibitors, Male, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury physiopathology, Nitric Oxide metabolism, Nitric Oxide Synthase antagonists & inhibitors, Nitric Oxide Synthase Type II physiology, Potassium Channel Blockers pharmacology, Rats, Rats, Sprague-Dawley, Receptors, Opioid, delta agonists, Receptors, Opioid, mu agonists, Cardiotonic Agents therapeutic use, Enkephalins therapeutic use, KATP Channels physiology, Myocardial Reperfusion Injury drug therapy, Nitric Oxide Synthase physiology
- Abstract
Background/aims: Eribis peptide 94 (EP 94) is a new enkephalin derivative which potently binds to the µ- and δ-opioid receptor. In this study, we determined the effects of EP 94 and potential mechanism(s) involved in cardioprotection of the rat heart., Methods and Results: An acute (5 and10 min into ischemia) and a chronic (24 h prior to ischemia) EP 94 administration produced a similar 30-40% reduction in infarct size/area at risk and the effects were blocked by the K(ATP) channel antagonists, HMR 1098 and 5-HD. The cardioprotective effects were blocked by a nonselective nitric oxide synthase (NOS) inhibitor (L-NAME) following acute administration and by a selective iNOS inhibitor (1400W) following chronic administration., Conclusion: These results suggest that EP 94 may have potential for the treatment of ischemic heart disease via a nitric oxide (NO)-K(ATP)-mediated mechanism., (Copyright © 2012 S. Karger AG, Basel.)
- Published
- 2012
- Full Text
- View/download PDF
44. Protection from myocardial ischemia/reperfusion injury by a positive allosteric modulator of the A₃ adenosine receptor.
- Author
-
Du L, Gao ZG, Nithipatikom K, Ijzerman AP, Veldhoven JP, Jacobson KA, Gross GJ, and Auchampach JA
- Subjects
- Adenosine pharmacology, Animals, Blood Pressure drug effects, Cardiovascular Agents pharmacology, Cell Membrane drug effects, Cell Membrane metabolism, Chromatography, High Pressure Liquid, Dogs, Female, Guanosine 5'-O-(3-Thiotriphosphate) metabolism, HEK293 Cells, Heart Rate drug effects, Humans, Male, Mass Spectrometry, Radioligand Assay, Ventricular Function, Left drug effects, Adenosine analogs & derivatives, Myocardial Reperfusion Injury prevention & control, Receptor, Adenosine A3 drug effects
- Abstract
Adenosine is increased in ischemic tissues where it serves a protective role by activating adenosine receptors (ARs), including the A₃ AR subtype. We investigated the effect of N-{2-[(3,4-dichlorophenyl)amino]quinolin-4-yl}cyclohexanecarboxamide (LUF6096), a positive allosteric modulator of the A₃ AR, on infarct size in a barbital-anesthetized dog model of myocardial ischemia/reperfusion injury. Dogs were subjected to 60 min of coronary artery occlusion and 3 h of reperfusion. Infarct size was assessed by macrohistochemical staining. Three experimental groups were included in the study. Groups I and II received two doses of vehicle or LUF6096 (0.5 mg/kg i.v. bolus), one administered before ischemia and the other immediately before reperfusion. Group III received a single dose of LUF6096 (1 mg/kg i.v. bolus) immediately before reperfusion. In preliminary in vitro studies, LUF6096 was found to exert potent enhancing activity (EC₅₀ 114.3 ± 15.9 nM) with the canine A₃ AR in a guanosine 5'-[γ-[³⁵S]thio]triphosphate binding assay. LUF6096 increased the maximal efficacy of the partial A₃ AR agonist 2-chloro-N⁶-(3-iodobenzyl)adenosine-5'-N-methylcarboxamide and the native agonist adenosine more than 2-fold while producing a slight decrease in potency. In the dog studies, administration of LUF6096 had no effect on any hemodynamic parameter measured. Pretreatment with LUF6096 before coronary occlusion and during reperfusion in group II dogs produced a marked reduction in infarct size (∼50% reduction) compared with group I vehicle-treated dogs. An equivalent reduction in infarct size was observed when LUF6096 was administered immediately before reperfusion in group III dogs. This is the first study to demonstrate efficacy of an A₃ AR allosteric enhancer in an in vivo model of infarction.
- Published
- 2012
- Full Text
- View/download PDF
45. The effect of NavX on fluoroscopy times in pediatric catheter ablation.
- Author
-
Kwong W, Neilson AL, Chiu CC, Gross GJ, Hamilton RM, Soucie L, Stephenson EA, and Kirsh JA
- Subjects
- Adolescent, Child, Child, Preschool, Electrophysiologic Techniques, Cardiac, Female, Humans, Infant, Male, Radiation Dosage, Tachycardia, Atrioventricular Nodal Reentry surgery, Accessory Atrioventricular Bundle surgery, Catheter Ablation, Fluoroscopy, Radiography, Interventional
- Abstract
Purpose: Catheter ablation is the established curative therapy for pediatric tachyarrhythmias. However, exposure to ionizing radiation from fluoroscopy during the procedure is of concern to both patients and caregivers. We sought to assess the impact of an impedance-based three-dimensional navigation system (NavX(TM), Endocardial Solutions, Inc., St. Paul, MN) on pediatric catheter ablation procedures., Methods: We retrospectively analyzed procedural data during a 7-year period (2002-2008), which spanned the transition between standard fluoroscopic mapping and adoption of NavX(TM) mapping for catheter ablation of atrioventricular nodal reentrant tachycardia (AVNRT) and right/left-sided accessory pathways (RAP/LAP). Comparisons of total procedure time, total fluoroscopy time, and ablation fluoroscopy time (from insertion of ablation catheter until completion of procedure) between NavX(TM) and conventional mapping were made., Results: Three hundred eighty-eight patients (aged 1-18 years, M/F 236:183) underwent ablation of AVNRT (n = 101), LAP (n = 130), or RAP (n = 157) using either conventional (n = 70) or NavX(TM) (n = 318) mapping. Overall success rates were similar between the two mapping approaches (95.7% for conventional versus 95.9% for NavX(TM)). NavX(TM) mapping significantly reduced ablation fluoroscopy time (15.9 ± 14.3 versus 11.0 ± 8.9 min for NavX(TM), p < 0.01) with a trend towards a decrease in total fluoroscopy time (26.4 ± 15.6 versus 23.8 ± 11.1 min for NavX(TM), p = 0.095). Total procedure time was not significantly different between the two methods (210.1 ± 66 versus 222.8 ± 61 min for NavX(TM), p = 0.13). When analyzed by arrhythmia substrate, there were significant reductions in ablation fluoroscopy time for both LAP and RAP., Conclusions: NavX(TM) mapping reduced ablation fluoroscopy times for accessory pathways during pediatric catheter ablation.
- Published
- 2012
- Full Text
- View/download PDF
46. Abdominal surgical incision induces remote preconditioning of trauma (RPCT) via activation of bradykinin receptors (BK2R) and the cytochrome P450 epoxygenase pathway in canine hearts.
- Author
-
Gross GJ, Baker JE, Moore J, Falck JR, and Nithipatikom K
- Subjects
- 8,11,14-Eicosatrienoic Acid analogs & derivatives, 8,11,14-Eicosatrienoic Acid pharmacology, Animals, Bradykinin analogs & derivatives, Bradykinin pharmacology, Bradykinin B2 Receptor Antagonists, Coronary Circulation drug effects, Cytochrome P-450 Enzyme Inhibitors, Disease Models, Animal, Dogs, Female, Hemodynamics drug effects, Ischemic Postconditioning methods, Male, Myocardial Infarction enzymology, Myocardial Infarction metabolism, Myocardial Infarction pathology, Myocardial Reperfusion Injury enzymology, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocardial Reperfusion Injury prevention & control, Abdomen surgery, Cytochrome P-450 Enzyme System metabolism, Ischemic Preconditioning, Myocardial methods, Myocardial Infarction prevention & control, Myocardium enzymology, Myocardium metabolism, Myocardium pathology, Receptor, Bradykinin B2 metabolism
- Abstract
Objective: Recently, a novel observation was made in which nonischemic trauma at a site remote from the heart produced by a transverse abdominal incision resulted in a marked reduction of infarct size (IS) in the mouse heart via activation of sensory nerve fibers in the skin and subsequent activation of bradykinin 2 receptors (BK2R). This phenomenon was termed remote preconditioning of trauma (RPCT). Since RPCT may have potential clinical implications we attempted to confirm these findings in a large animal model, the dog. The epoxyeicosatrienoic acids (EETs) have also recently been shown to be antinociceptive and have been shown to mimic ischemic preconditioning (IPC) and postconditioning (POC) in dogs, therefore, we tested the role of the EETs in RPCT., Methods: Anesthetized adult mongrel dogs of either sex were subjected to 60 min of left anterior descending (LAD) coronary artery occlusion followed by 3 h of reperfusion. In all groups except the controls (no slit), a transverse slit (9 cm) was applied to the abdominal wall of the dog being careful to only slit the skin. Subsequently, 15 min after the slit the heart was subjected to the ischemia/reperfusion protocol., Results: In the control dogs, the IS as a percent of the area at risk (AAR) was 22.5 ± 2.4%, whereas in the dogs subjected to the slit alone the IS/AAR was reduced to 9.2 ± 1.2% (*P < 0.01). The BR2R blocker, HOE 140 (50 ug/kg, iv) given 10 min prior to the slit, completely abolished the protective effects of RCPT as did pretreatment with 14,15-EEZE, a putative EET receptor blocker or pretreatment with the selective EET synthesis inhibitor, MSPPOH., Conclusions: These results suggest that BK and the EETs share cardioprotective properties in a large animal model of RPCT.
- Published
- 2011
- Full Text
- View/download PDF
47. Arrhythmia and sudden death associated with elevated cardiac chloride channel activity.
- Author
-
Ye L, Zhu W, Backx PH, Cortez MA, Wu J, Chow YH, McKerlie C, Wang A, Tsui LC, Gross GJ, and Hu J
- Subjects
- Animals, Arrhythmias, Cardiac chemically induced, Atrioventricular Block chemically induced, Bradycardia chemically induced, Cardiac Pacing, Artificial, Cystic Fibrosis Transmembrane Conductance Regulator biosynthesis, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Heart, In Situ Hybridization, Isoproterenol administration & dosage, Isoproterenol pharmacology, Mice, Mice, Inbred C57BL, Mice, Transgenic, Tachycardia, Ventricular, Arrhythmias, Cardiac metabolism, Atrioventricular Node physiopathology, Chloride Channels metabolism, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Death, Sudden, Cardiac, Heart Conduction System physiopathology, Myocardium metabolism
- Abstract
The identification and analysis of several cationic ion channels and their associated genes have greatly improved our understanding of the molecular and cellular mechanisms of cardiac arrhythmia. Our objective in this study was to examine the involvement of anionic ion channels in cardiac arrhythmia. We used a transgenic mouse model to overexpress the human cystic fibrosis transmembrane conductance regulator (CFTR) gene, which encodes a cAMP-regulated chloride channel. We used RNase protection and in situ hybridization assays to determine the level of CFTR expression, and radiotelemetry and in vivo electrophysiological study in combination with pharmacological intervention to analyse the cardiac function. Cardiac CFTR overexpression leads to stress-related sudden death in this model. In vivo intracardiac electrophysiological studies performed in anaesthetized mice showed no significant differences in baseline conduction parameters including atrial-His bundle (AH) or His bundle-ventricular (HV) conduction intervals, atrioventricular (AV) Wenckebach or 2:1 AV block cycle length and AV nodal functional refractory period. However, following isoproterenol administration, there was marked slowing of conduction parameters, including high-grade AV block in transgenic mice, with non-sustained ventricular tachycardia easily inducible using programmed stimulation or burst pacing. Our sudden death mouse model can be a valuable tool for investigation of the role of chloride channels in arrhythmogenesis and, potentially, for future evaluation of novel anti-arrhythmic therapeutic strategies and pharmacological agents., (© 2011 The Authors Journal of Cellular and Molecular Medicine © 2011 Foundation for Cellular and Molecular Medicine/Blackwell Publishing Ltd.)
- Published
- 2011
- Full Text
- View/download PDF
48. The neonatal but not the mature heart adapts to acute tachycardia by beneficial modification of the force-frequency relationship.
- Author
-
Schmidt MR, White PA, Khambadkone S, Gross GJ, Bøtker HE, Vogel M, Hjortdal VE, Sørensen KE, and Redington AN
- Subjects
- Age Factors, Animals, Calcium Channels drug effects, Calcium Channels physiology, Cardiac Pacing, Artificial, Cardiotonic Agents pharmacology, Cytoplasm drug effects, Cytoplasm metabolism, Cytosol drug effects, Cytosol metabolism, Digoxin pharmacology, Electrocardiography drug effects, Heart Failure physiopathology, Heart Rate drug effects, Models, Theoretical, Myocardial Contraction drug effects, Sarcoplasmic Reticulum drug effects, Sarcoplasmic Reticulum physiology, Swine, Ventricular Function, Left drug effects, Ventricular Function, Left physiology, Animals, Newborn, Heart Rate physiology, Myocardial Contraction physiology, Tachycardia physiopathology
- Abstract
The force-frequency relationship (FFR) reflects alterations in intracellular calcium cycling during changing heart rate (HR). Tachycardia-induced heart failure is associated with depletion of intracellular calcium. We hypothesized (1) that the relative resistance to tachycardia-induced heart failure seen in neonatal pigs is related to differences in calcium cycling, resulting in different FFR responses and (2) that pretreatment with digoxin to increase intracellular calcium would modifies these changes. LV +dP/dt was measured during incremental right atrial pacing in 16 neonatal and 14 adult pigs. FFR was measured as the change in +dP/dt as HR was increased. Animals were randomized to control or intravenous bolus digoxin (n = 8 neonate pigs in the 0.05 mg/kg group and n = 7 adult pigs in the 0.025 mg/kg group) and paced for 90 min at 25 bpm greater than the rate of peak +dP/dt. Repeat FFR was then obtained. The postpacing FFR in neonatal control pigs shifted rightward, with peak force occurring 30 bpm greater than baseline (P < 0.03). There was no vertical shift; thus, force at 150 bpm decreased (P < 0.03) and force at 300 beats/min increased (P < 0.08). In adult control pigs, FFR shifted downward (P < 0.01), with decreased force generation at all HRs. In both neonates and adult pigs, digoxin increased +dP/dt at all HRs; however, in neonate pigs digoxin decreased the contractile reserve by abrogation of the rightward shift of FFR. An adaptive response to tachycardia in the neonate pig leads to improved force generation at greater HRs. Conversely, the response of the mature pig heart is maladaptive with decreased force generation. Pretreatment with digoxin modifies these responses.
- Published
- 2011
- Full Text
- View/download PDF
49. Characterization of a critical role for CFTR chloride channels in cardioprotection against ischemia/reperfusion injury.
- Author
-
Xiang SY, Ye LL, Duan LL, Liu LH, Ge ZD, Auchampach JA, Gross GJ, and Duan DD
- Subjects
- Animals, Apoptosis, Caspase 3 metabolism, Cystic Fibrosis Transmembrane Conductance Regulator genetics, Cystic Fibrosis Transmembrane Conductance Regulator metabolism, Disease Models, Animal, Male, Mice, Mice, Inbred CFTR, Mice, Knockout, Myocardial Reperfusion Injury metabolism, Myocardial Reperfusion Injury pathology, Myocardium metabolism, Myocardium pathology, Perfusion, Cystic Fibrosis Transmembrane Conductance Regulator physiology, Ischemic Postconditioning, Ischemic Preconditioning, Myocardial, Myocardial Reperfusion Injury prevention & control
- Abstract
Aim: To further characterize the functional role of cystic fibrosis transmembrane conductance regulator (CFTR) in early and late (second window) ischemic preconditioning (IPC)- and postconditioning (POC)-mediated cardioprotection against ischemia/reperfusion (I/R) injury., Methods: CFTR knockout (CFTR(-/-)) mice and age- and gender-matched wild-type (CFTR(+/+)) and heterozygous (CFTR(+/-)) mice were used. In in vivo studies, the animals were subjected to a 30-min coronary occlusion followed by a 40-min reperfusion. In ex vivo (isolate heart) studies, a 45-min global ischemia was applied. To evaluate apoptosis, the level of activated caspase 3 and TdT-mediated dUTP-X nick end labeling (TUNEL) were examined., Results: In the in vivo I/R models, early IPC significantly reduced the myocardial infarct size in wild-type (CFTR(+/+)) (from 40.4% ± 5.3% to 10.4% ± 2.0%, n=8, P<0.001) and heterozygous (CFTR(+/-)) littermates (from 39.4% ± 2.4% to 15.4% ± 5.1%, n=6, P<0.001) but failed to protect CFTR knockout (CFTR(-/-)) mice from I/R induced myocardial infarction (46.9% ± 6.2% vs 55.5% ± 7.8%, n=6, P>0.5). Similar results were observed in the in vivo late IPC experiments. Furthermore, in both in vivo and ex vivo I/R models, POC significantly reduced myocardial infarction in wild-type mice, but not in CFTR knockout mice. In ex vivo I/R models, targeted inactivation of CFTR gene abolished the protective effects of IPC against I/R-induced apoptosis., Conclusion: These results provide compelling evidence for a critical role for CFTR Cl(-) channels in IPC- and POC-mediated cardioprotection against I/R-induced myocardial injury.
- Published
- 2011
- Full Text
- View/download PDF
50. Effect on ex vivo platelet aggregation and in vivo cyclic flow with Na+/H+ exchange inhibition: Gumina, NHE-1 inhibition and platelet aggregation.
- Author
-
Gumina RJ, Newman PJ, and Gross GJ
- Subjects
- Animals, Blood Flow Velocity, Disease Models, Animal, Dogs, Femoral Artery metabolism, Humans, Benzamides pharmacology, Blood Platelets metabolism, Femoral Artery injuries, Mesylates pharmacology, Platelet Aggregation drug effects, Pyrroles pharmacology, Sodium-Hydrogen Exchangers antagonists & inhibitors
- Abstract
BIIB 513 and EMD 85131 are selective inhibitors of the Na+/H+ exchanger-1 (NHE-1) that are benzoylguanidine derivatives of the clinically employed diuretic amiloride. Prior studies have suggested a role for NHE-1 activity in platelet activation and aggregation using amiloride or its non- benzoylguanidines derivatives. However, the concentrations employed in these prior studies were at levels known to exert effects on other ion transport systems besides the NHE-1. Therefore, the purpose of this study was to examine the effects of more selective NHE-1 inhibitors, BIIB 513 and EMD 85131, on platelet aggregation and in vivo cyclic flow following arterial injury. BIIB 513 and EMD 85131 effects on ex vivo canine and human platelet aggregation in response to various agents was monitored via platelet aggregation. For analysis of in vivo thrombus formation, a femoral artery crush injury model was employed and a flow meter was used to monitor the effect of BIIB 513 on cyclic blood flow. Treatment of either canine or human platelets with up to 1 mM of BIIB 513 had no effect on aggregation induced by platelet activating factor (PAF), thrombin receptor activator peptide (TRAP), or adenosine diphosphate (ADP). Additionally, the structurally related compound EMD 85131 at up to 1 mM failed to inhibit TRAP induced platelet aggregation. In vivo administration of up to 9 mg/kg of BIIB 513 intravenously failed to affect cyclic flow in a canine model of femoral artery injury. These data demonstrate that the specific and selective NHE-1 inhibitors BIIB 513 or EMD 85131 have no effect on ex vivo platelet aggregation or in vivo cyclic flow following arterial injury.
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.